Filtered By:
Drug: Doxycycline

This page shows you your search results in order of date.

Order by Relevance | Date

Total 35 results found since Jan 2013.

The autophagic protein FYCO1 controls TNFRSF10/TRAIL receptor induced apoptosis and is inactivated by CASP8 (caspase 8)
Autophagy. 2023 Jul 7:1-19. doi: 10.1080/15548627.2023.2229656. Online ahead of print.ABSTRACTApoptosis is a tightly controlled cell death program executed by proteases, the so-called caspases. It plays an important role in tissue homeostasis and is often dysregulated in cancer. Here, we identified FYCO1, a protein that promotes microtubule plus end-directed transport of autophagic and endosomal vesicles as a molecular interaction partner of activated CASP8 (caspase 8). The absence of FYCO1 sensitized cells to basal and TNFSF10/TRAIL-induced apoptosis by receptor accumulation and stabilization of the Death Inducing Signali...
Source: Autophagy - July 7, 2023 Category: Cytology Authors: Valeria Coppola Ilaria Marino Uwe Warnken Mario Falchi Luca Pasquini Mauro Biffoni Ruggero De Maria Tobias Longin Haas Source Type: research

Atypical induction of HIF-1 α expression by pericellular Notch1 signaling suffices for the malignancy of glioblastoma multiforme cells
Cell Mol Life Sci. 2022 Oct 2;79(10):537. doi: 10.1007/s00018-022-04529-2.ABSTRACTContact-based pericellular interactions play important roles in cancer progression via juxtacrine signaling pathways. The present study revealed that hypoxia-inducible factor-1α (HIF-1α), induced even in non-hypoxic conditions by cell-to-cell contact, was a critical cue responsible for the malignant characteristics of glioblastoma multiforme (GBM) cells through Notch1 signaling. Densely cultured GBM cells showed enhanced viability and resistance to temozolomide (TMZ) compared to GBM cells at a low density. Ablating Notch1 signaling by a γ-...
Source: Cellular and Molecular Life Sciences : CMLS - October 2, 2022 Category: Cytology Authors: Jungwhoi Lee Eunsoo Kim Kyuha Chong Seung-Wook Ryu Chungyeul Kim Kyungsun Choi Jae-Hoon Kim Chulhee Choi Source Type: research

Silencing of Mcl-1 overcomes resistance of melanoma cells against TRAIL-armed oncolytic adenovirus by enhancement of apoptosis
J Mol Med (Berl). 2021 May 24. doi: 10.1007/s00109-021-02081-3. Online ahead of print.ABSTRACTArming of oncolytic viruses with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown as a viable approach to increase the antitumor efficacy in melanoma. However, melanoma cells may be partially or completely resistant to TRAIL or develop TRAIL resistance, thus counteracting the antitumor efficiency of TRAIL-armed oncolytic viruses. Recently, we found that TRAIL resistance in melanoma cells can be overcome by inhibition of antiapoptotic Bcl-2 protein myeloid cell leukemia 1 (Mcl-1). Here, we investigated...
Source: Molecular Medicine - May 24, 2021 Category: Molecular Biology Authors: Beatrice Tolksdorf Sina Zarif J ürgen Eberle Ahmet Hazini Babette Dieringer Franziska J önsson Florian Kreppel Jens Kurreck Henry Fechner Source Type: research

Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis
Transthyretin (TTR) is a tetrameric transport protein that causes amyloid formation if destabilized. ATTR ‐amyloidosis is a progressive systemic disease with polyneuropathy and cardiomyopathy as the most abundant manifestations. Approved treatment approaches comprise sequence‐specific mRNA degradation and tetramer stabilization. Ongoing clinical trials assess the potential of GalNAc formulations to improve the administration of small interfering RNA and antisense oligonucleotides. A future TTR‐stabilizer with the potential to cross the blood‐brain barrier is tolcapone. Amyloid‐directed antibodies aim at reducing ...
Source: Journal of Neurochemistry - April 2, 2021 Category: Neuroscience Authors: Maike F. Dohrn, Sandra Ihne, Ute Hegenbart, Jessica Medina, Stephan L. Z üchner, Teresa Coelho, Katrin Hahn Tags: Review Article Source Type: research

GSE163646 MITF reprograms the extracellular matrix and focal adhesion in melanoma
Contributor : Ramile DilshatSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensTo assess the effects of permanent loss of MITF in melanoma cells, we used the clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9 technique to generate MITF knockout (KO) cell lines in the human hypo-tetraploid SkMel28 melanoma cell line (containing four copies of MITF). We targeted exon 6 (containing the DNA binding domain) of MITF the resulting isogenic cell line is hereafter referred to as ΔMITF-X6. We also performed siRNA mediated transient knock down of MITF along with control siCTRL...
Source: GEO: Gene Expression Omnibus - December 22, 2020 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Homo sapiens Source Type: research

Targeting transthyretin ‐ Mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis
Transthyretin (TTR) is a tetrameric transport protein that causes amyloid formation if destabilized. ATTR ‐amyloidosis is a progressive systemic disease with polyneuropathy and cardiomyopathy as the most abundant manifestations. Approved treatment approaches comprise sequence‐specific mRNA degradation and tetramer stabilization. Ongoing clinical trials assess the potential of GalNAc formulations to improve the administration of small interfering RNA and antisense oligonucleotides. A future TTR‐stabilizer with the potential to cross the blood‐brain barrier is tolcapone. Amyloid‐directed antibodies aim at reducing ...
Source: Journal of Neurochemistry - December 3, 2020 Category: Neuroscience Authors: Maike F. Dohrn, Sandra Ihne, Ute Hegenbart, Jessica Medina, Stephan L. Z üchner, Teresa Coelho, Katrin Hahn Tags: Review Article Source Type: research

Targeting transthyretin – mechanism‐based treatment approaches and future perspectives in hereditary amyloidosis
AbstractThe liver ‐derived, circulating transport protein transthyretin (TTR) is the cause of systemic hereditary (ATTRv) and wildtype (ATTRwt) amyloidosis. TTR stabilization and knockdown are approved therapies to mitigate the otherwise lethal disease course. To date, the variety in phenotypic penetrance and organ tropism is not fully understood. This systematic review summarizes the current literature on TTR pathophysiology with its therapeutic implications. Tetramer dissociation is the rate‐limiting step of amyloidogenesis. Besides destabilizingTTR mutations, other genetic (RBP4,APCS, AR, ATX2, C1q, C3) and external...
Source: Journal of Neurochemistry - November 6, 2020 Category: Neuroscience Authors: Maike F. Dohrn, Sandra Ihne, Ute Hegenbart, Jessica Medina, Stephan Z üchner, Teresa Coelho, Katrin Hahn Tags: REVIEW Source Type: research

Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer
ConclusionsER β2/ERβ5 and ERβ1 exhibit sharply contrasting activities in TNBC cells. Our findings imply that delineating the absolute amounts and relative ratios of the different ERβ isoforms might have prognostic and therapeutic relevance, and could enable better selection of optimal approaches for treatment of this often aggressive form of breast cancer.
Source: Breast Cancer Research and Treatment - September 30, 2020 Category: Cancer & Oncology Source Type: research

Cancers, Vol. 11, Pages 1490: CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis
Agarwal Rosenthal CD133, known as prominin1, is a penta-span transmembrane glycoprotein presumably acancer stem cell marker for carcinomas, glioblastomas, and melanomas. We showed that CD133(+)‘melanoma-initiating cells’ are associated with chemoresistance, contributing to poor patientoutcome. The current study investigates the role(s) of CD133 in invasion and metastasis. Magneticactivatedcell sorting of a melanoma cell line (BAKP) followed by transwell invasion assays revealedthat CD133(+) cells are significantly more invasive than CD133(−) cells. Conditional reprogramm...
Source: Cancers - October 2, 2019 Category: Cancer & Oncology Authors: Simbulan-Rosenthal Dougherty Vakili Ferraro Kuo Alobaidi Aljehane Gaur1 Sykora Glasgow Agarwal Rosenthal Tags: Article Source Type: research

Inactivation of MTOR promotes autophagy-mediated epithelial injury in particulate matter-induced airway inflammation.
Abstract Particulate matter (PM) is able to induce airway epithelial injury, while the detailed mechanisms remain unclear. Here we demonstrated that PM exposure inactivated MTOR (mechanistic target of rapamycin kinase), enhanced macroautophagy/autophagy, and impaired lysosomal activity in HBE (human bronchial epithelial) cells and in mouse airway epithelium. Genetic or pharmaceutical inhibition of MTOR significantly enhanced, while inhibition of autophagy attenuated, PM-induced IL6 expression in HBE cells. Consistently, club-cell-specific deletion of Mtor aggravated, whereas loss of Atg5 in bronchial epithelium re...
Source: Autophagy - June 15, 2019 Category: Cytology Authors: Wu YF, Li ZY, Dong LL, Li WJ, Wu YP, Wang J, Chen HP, Liu HW, Li M, Jin CL, Huang HQ, Ying SM, Li W, Shen HH, Chen ZH Tags: Autophagy Source Type: research

Blockade of Ubiquitin Receptor PSMD4/Rpn10 Triggers Cytotoxicity and Overcomes Bortezomib-Resistance in Multiple Myeloma
ConclusionOur preclinical data validates targeting 19S proteasome ubiquitin receptor Rpn10 upstream of the proteasome in the ubiquitin proteasomal cascade, and provides the framework for clinical evaluation of Rpn10 inhibitors to overcome PI resistance and improve patient outcome in MM.DisclosuresAnderson: C4 Therapeutics: Equity Ownership, Other: Scientific founder; Celgene: Consultancy; Bristol Myers Squibb: Consultancy; Gilead: Membership on an entity's Board of Directors or advisory committees; Millennium Takeda: Consultancy; OncoPep: Equity Ownership, Other: Scientific founder.
Source: Blood - November 21, 2018 Category: Hematology Authors: Song, Y., Ray, A., Chauhan, D., Anderson, K. Tags: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Poster II Source Type: research